Home/Filings/4/0000950170-25-050558
4//SEC Filing

Lister Troy 4

Accession 0000950170-25-050558

CIK 0001840574other

Filed

Apr 2, 8:00 PM ET

Accepted

Apr 3, 5:00 PM ET

Size

11.4 KB

Accession

0000950170-25-050558

Insider Transaction Report

Form 4
Period: 2025-04-01
Lister Troy
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2025-04-013,3156,630 total
    Common Stock (3,315 underlying)
  • Exercise/Conversion

    Common Stock

    2025-04-01+7,3409,141 total
  • Sale

    Common Stock

    2025-04-02$4.15/sh2,189$9,0846,952 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-04-014,02512,075 total
    Common Stock (4,025 underlying)
Footnotes (4)
  • [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
  • [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 20, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
  • [F3]On February 14, 2023, the reporting person was granted 13,260 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2024 and the remainder vesting in equal annual installments until April 1, 2027.
  • [F4]On February 14, 2024, the reporting person was granted 16,100 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.

Documents

1 file

Issuer

Verve Therapeutics, Inc.

CIK 0001840574

Entity typeother

Related Parties

1
  • filerCIK 0002023489

Filing Metadata

Form type
4
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 5:00 PM ET
Size
11.4 KB